Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another week, more promises and and a whole lot of NOTHING. Unfortunately Gator, you speak the truth.
Great Post, Litchfield, should be put on the sticky board.
BIOELECTRONICS CORPORATION PUBLISHED FACTS
BioElectronics Corporation was organized in Maryland in April 2000. It develops, manufactures, and markets drug free, disposable, topical pain medical devices. Its products comprise ActiPatch therapy for over-the-counter treatment of back pain and other musculoskeletal complaints; Allay menstrual cycle pain therapy; RecoveryRx for chronic and post-operative wound care; and HealFast therapy, a drug-free therapy for healing of muscle and tendon injuries, sores, and incision in horses, cats, and dogs. The company markets and sells its products under the ActiPatch, Allay, and RecoveryRx brand names through distributors in over 50 countries.
ActiPatch does fit into new Class II
BioElectronics Corporation has United States Patent and Trademark Office patent protection until at least 2030.
Best selling pain item on Amazon UK, Europe and Canada.
Are shareholders and public entitled to know Bioelectronics business tactics? No, not a good business practice.
Is the 90 days just an estimate for Approval by the FDA? Yes
Does the 90 days just include FDA Days? Yes.
Does elapsed time include FDA Days and FDA Hold Days? Yes
Can a 510(k) assessment clear a device in a week or two? Yes it can.
Does that happen often? Not very often.
Is the main reason for hiring experts to do a 510(k), to get it right and avoid Additional Information requests. Yes
Are Additional Information requests pretty common? Yes, FDA issues many requests every day for more data or clarifications as required.
DO YOUR OWN DUE DILIGENCE WHEN INVESTING. GO BIEL!!!
BIOELECTRONICS CORPORATION ACCOMPLISHMENTS:
Nov. 9, 2015 - Leading UK Retailer, Superdrug to market and sell ActiPatch® Pain Therapy. Superdrug is a subsidiary of the A.S. Watson Group, the world’s largest international health and beauty retailer with 12,000 stores.
Oct. 20, 2015 - BioElectronics Corporation announced that it has received initial orders for its ActiPatch® Musculoskeletal Pain Relief products for 1,077 Lloyd's pharmacies, the second largest chain in the UK and Gordons Chemists which has over 60 pharmacies in shopping centers across Scotland and Northern Ireland. ActiPatch will be on promotion in stores and online beginning November 1.
October 13, 2015 - The Food and Drug Administration (FDA) is issuing a final order to reclassify shortwave diathermy (SWD) for all other uses, a preamendments class III device, into class II (special controls), and to rename the device “nonthermal shortwave therapy” (SWT). FDA is also making a technical correction in the regulation for the carrier frequency for SWD and SWT devices.
August 6, 2015 – BioElectronics Corporation submitted new 510(k) application at the recommendation and invitation of FDA.
June 30, 2015 - 8,000,000,000 shares authorized and 7,999,028,602 shares issued and outstanding at June 30, 2015.
June 30, 2015 - Sales were up 164% for the first 6 months. June 30, 2015 sales: $1,178,796 June 30, 2014 sales: $446,280
May 15, 2015 - the Therapeutic Products Directorate, Medical Devices Bureau of Health Canada has issued a Class II License for the RecoveryRx™ Post-Surgical and Wound Care Recovery product. The license means that the product can be sold Over-the-Counter (OTC) in Canada. RecoveryRx uses pulsed electromagnetic field therapy to reduce pain and inflammation and promote healing of injured tissue.
February 9, 2015 - B. Braun Medical Ltd announced as exclusive distributors for RecoveryRx in the UK and Ireland. B. Braun has over $6 billion in annual sales and is the 12th largest device companies in World.
December 9, 2013 - BioElectronics Corporation announced that Boots, the UK‘s premiere health and beauty retailer is selling its ActiPatch® Pain Therapy products in 585 select stores in the UK and Ireland for back, knee and musculoskeletal ailments.
2010 - Allay™ Menstrual Pain Therapy product has been approved for over the counter sale by Health Canada for the treatment of menstrual pain symptoms, including cramps and abdominal pain.
2005 - Health Canada approves ActiPatch Therapy for relief of pain in musculoskeletal
complaints.
2004 - US Medicare and Medicaid agree to reimburse for electromagnetic treatment of chronic Stage III and IV wounds.
2004 - The Company received ISO and CE (European Common Market)
certification. For low dose ActiPatch Therapy as a Class II medical device.
2002 - U.S. FDA approves low dose, extended duration ActiPatch Therapy for the treatment of edema following blepharoplasty.
Litchfield, will that be in the form of a NT-10-Q or will there be some actual news?
GO BTZO!!
GREAT POST SIMPSONLY, SHOULD GET A STICKY
Response: We are working on it, there is a lot going on and if you believe that, I have a bridge to sell you.
THESE ARE PUBLISHED FACTS REGARDING BIOELECTRONICS CORPORATION. DO YOUR OWN DUE DILIGENCE WHEN INVESTING.
BioElectronics Corporation was organized in Maryland in April 2000. It develops, manufactures, and markets drug free, disposable, topical pain medical devices. Its products comprise ActiPatch therapy for over-the-counter treatment of back pain and other musculoskeletal complaints; Allay menstrual cycle pain therapy; RecoveryRx for chronic and post-operative wound care; and HealFast therapy, a drug-free therapy for healing of muscle and tendon injuries, sores, and incision in horses, cats, and dogs. The company markets and sells its products under the ActiPatch, Allay, and RecoveryRx brand names through distributors in over 50 countries.
BioElectronics Corporation accomplishments:
2002 - U.S. FDA approves low dose, extended duration ActiPatch Therapy for the treatment of edema following blepharoplasty.
2004 - The Company received ISO and CE (European Common Market)
certification. For low dose ActiPatch Therapy as a Class II medical device.
2004 - US Medicare and Medicaid agree to reimburse for electromagnetic treatment of chronic Stage III and IV wounds.
2005 - Health Canada approves ActiPatch Therapy for relief of pain in musculoskeletal
complaints.
2010 - Allay™ Menstrual Pain Therapy product has been approved for over the counter sale by Health Canada for the treatment of menstrual pain symptoms, including cramps and abdominal pain.
December 9, 2013 - BioElectronics Corporation announced that Boots, the UK‘s premiere health and beauty retailer is selling its ActiPatch® Pain Therapy products in 585 select stores in the UK and Ireland for back, knee and musculoskeletal ailments.
February 9, 2015 - B. Braun Medical Ltd announced as exclusive distributors for RecoveryRx in the UK and Ireland. B. Braun has over $6 billion in annual sales and is the 12th largest device companies in World.
May 15, 2015 - the Therapeutic Products Directorate, Medical Devices Bureau of Health Canada has issued a Class II License for the RecoveryRx™ Post-Surgical and Wound Care Recovery product. The license means that the product can be sold Over-the-Counter (OTC) in Canada. RecoveryRx uses pulsed electromagnetic field therapy to reduce pain and inflammation and promote healing of injured tissue.
August 6, 2015 – BioElectronics Corporation submitted new 510(k) application at the recommendation and invitation of FDA.
October 13, 2015 - The Food and Drug Administration (FDA) is issuing a final order to reclassify shortwave diathermy (SWD) for all other uses, a preamendments class III device, into class II (special controls), and to rename the device “nonthermal shortwave therapy” (SWT). FDA is also making a technical correction in the regulation for the carrier frequency for SWD and SWT devices.
Oct. 20, 2015 - BioElectronics Corporation announced that it has received initial orders for its ActiPatch® Musculoskeletal Pain Relief products for 1,077 Lloyd's pharmacies, the second largest chain in the UK and Gordons Chemists which has over 60 pharmacies in shopping centers across Scotland and Northern Ireland. ActiPatch will be on promotion in stores and online beginning November 1.
BioElectronics Corporation has United States Patent and Trademark Office patent protection until at least 2030.
Best selling pain item on Amazon UK, Europe and Canada.
June 30, 2015 - 8,000,000,000 shares authorized and 7,999,028,602 shares issued and outstanding at June 30, 2015.
June 30, 2015 - Sales were up 164% for the first 6 months. June 30, 2015 sales: $1,178,796 June 30, 2014 sales: $446,280
THESE ARE PUBLISHED FACTS REGARDING BIOELECTRONICS CORPORATION. DO YOUR OWN DUE DILIGENCE WHEN INVESTING.
BioElectronics Corporation was organized in Maryland in April 2000. It develops, manufactures, and markets drug free, disposable, topical pain medical devices. Its products comprise ActiPatch therapy for over-the-counter treatment of back pain and other musculoskeletal complaints; Allay menstrual cycle pain therapy; RecoveryRx for chronic and post-operative wound care; and HealFast therapy, a drug-free therapy for healing of muscle and tendon injuries, sores, and incision in horses, cats, and dogs. The company markets and sells its products under the ActiPatch, Allay, and RecoveryRx brand names through distributors in over 50 countries.
BioElectronics Corporation accomplishments:
2002 - U.S. FDA approves low dose, extended duration ActiPatch Therapy for the treatment of edema following blepharoplasty.
2004 - The Company received ISO and CE (European Common Market)
certification. For low dose ActiPatch Therapy as a Class II medical device.
2004 - US Medicare and Medicaid agree to reimburse for electromagnetic treatment of chronic Stage III and IV wounds.
2005 - Health Canada approves ActiPatch Therapy for relief of pain in musculoskeletal
complaints.
2010 - Allay™ Menstrual Pain Therapy product has been approved for over the counter sale by Health Canada for the treatment of menstrual pain symptoms, including cramps and abdominal pain.
December 9, 2013 - BioElectronics Corporation announced that Boots, the UK‘s premiere health and beauty retailer is selling its ActiPatch® Pain Therapy products in 585 select stores in the UK and Ireland for back, knee and musculoskeletal ailments.
February 9, 2015 - B. Braun Medical Ltd announced as exclusive distributors for RecoveryRx in the UK and Ireland. B. Braun has over $6 billion in annual sales and is the 12th largest device companies in World.
May 15, 2015 - the Therapeutic Products Directorate, Medical Devices Bureau of Health Canada has issued a Class II License for the RecoveryRx™ Post-Surgical and Wound Care Recovery product. The license means that the product can be sold Over-the-Counter (OTC) in Canada. RecoveryRx uses pulsed electromagnetic field therapy to reduce pain and inflammation and promote healing of injured tissue.
August 6, 2015 – BioElectronics Corporation submitted new 510(k) application at the recommendation and invitation of FDA.
October 13, 2015 - The Food and Drug Administration (FDA) is issuing a final order to reclassify shortwave diathermy (SWD) for all other uses, a preamendments class III device, into class II (special controls), and to rename the device “nonthermal shortwave therapy” (SWT). FDA is also making a technical correction in the regulation for the carrier frequency for SWD and SWT devices.
Oct. 20, 2015 - BioElectronics Corporation announced that it has received initial orders for its ActiPatch® Musculoskeletal Pain Relief products for 1,077 Lloyd's pharmacies, the second largest chain in the UK and Gordons Chemists which has over 60 pharmacies in shopping centers across Scotland and Northern Ireland. ActiPatch will be on promotion in stores and online beginning November 1.
BioElectronics Corporation has United States Patent and Trademark Office patent protection until at least 2030.
Best selling pain item on Amazon UK, Europe and Canada.
June 30, 2015 - 8,000,000,000 shares authorized and 7,999,028,602 shares issued and outstanding at June 30, 2015.
June 30, 2015 - Sales were up 164% for the first 6 months. June 30, 2015 sales: $1,178,796 June 30, 2014 sales: $446,280
As the Guitarzman posted: "With the recent onslaught of negativity being posted and the desperate attempts to create doubt among investors or would be investors, there must be some good news on the horizon for this company. It appears that someone hit the Panic button."
GO BIEL!!!
Good news coming - Hell, I would settle for them just filing the 10-Q on time.
Great Post, Guitarzman!! Deserving of a sticky. GO BIEL!!!!
Marilu Brassington's email address at Linkedin
Possible way to contact Marilu Brasington Calvez, Chief Financial Officer at Democratique DBA Bitzio
https://www.linkedin.com/pub/marilu-brassington-calvez/7b/194/867
Walgreens Boots Alliance nears deal to buy Rite Aid. This might bode well for BIEL. A lot more markets.
What numbers does the sec call when they want to talk to company officers?
None!! They go to Facebook, the same place stockholders have to go to get company information.
Cease Trade Order only exists in British Columbia, looks like some missing paperwork. No problems with our SEC.
British Columbia Securities Commission
Tel: 604 899-6500 Fax: 604 899-6506 Toll Free: 1 800-373-6393 www.bcsc.bc.ca
P.O. Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, BC, Canada V7Y 1L2
Citation: 2015 BCSECCOM 146
Cease Trade Order
Bitzio, Inc.
DynaResource, Inc.
Portus Corporation
Quest Water Global, Inc.
St. Joseph, Inc.
(each referred to separately as the Reporting Issuer)
Section 164 of the Securities Act, R.S.B.C. 1996, c. 418
¶ 1 The Reporting Issuer is an OTC reporting issuer under Multilateral Instrument 51-105
Issuers Quoted in the U.S. Over-the-Counter Markets (MI 51-105).
¶ 2 The Reporting Issuer has not filed:
1. a Form 51-102F2 Annual Information Form for the year ended December 31, 2014
as required under section 5(c) of MI 51-105
(the required record).
¶ 3 Under section 164(1) of the Act, the Executive Director orders that all trading in the
securities of the Reporting Issuer cease until:
1. it files the required records, completed in accordance with the Act and rules, and
2. the Executive Director revokes this order.
¶ 4 April 23, 2015
Michael L. Moretto, CA, CPA (Illinois)
Manager
Corporate Finance
What ever float your boat.
Hey russb1, don't go. We need your's and gatorhistory's objectivity. Everything ain't rosy with this company. Obvious by the lack of communication, PPS performance, rumors and innuendos. The stockholders (I'm one) just don't want to admit how bad it really is. Why, because we know we could lose all our hard earned monies invested in the company, so we cling to that little glimmer of hope. But, for now, Still Hoping!!!
Correct!! Also, supposedly communicating to one or two Ihub boardmembers, could also be illegal in the SEC's eyes. Leaking insider information??
Amen to you gatorhistory, but you forgot to add that hopefully by 2018 we may have actually received a PR from Hub.
You hit the nail on the head with that post, gatorhistory. Totally incompetent
Hubs "experience" What experience?? You can't build a start up company without PR. In order to grow, people need to know about you. Your products, services, sales, forward looking statements, etc. So far gatorhistory, you are totally correct: A SHAM!!!!
A very good opinion!!! We seem to be dealing with a CEO?? who is in over his head.
Penny stocks with 6,000,000,000 shares outstanding usually aren't in the mid .00's ???
Sirius XM (SIRI) was on the verge of bankruptcy in 2009. On 09/30/2009, it was trading at $0.63 per share, up from $0.12 in January, 2009. As of the end of September 30, 2009, Sirius had authorized 9 billion shares of which 3.9 billion were issued. They received outside financing which led to their turn around.
It can happen!!! GO BTZO
Beautiful, Simsonly!! That deserves a sticky!! GO BIEL, GO LONGS!!
Eagles13, you might have to start another website blitz. Your last efforts were successful in getting Hub to prove he wasn't dead. Now, you need to find out from the Hub man, if we shareholders are still alive.
Whale crap, that's a good one seven!! GO BIEL, GO LONGS!!
Can't wait to actually see something that is official from hub or marilu, just as long is it's not another NT 10-Q
Financials mean nothing if HUB continues to hide. Eagles13, didn't you get the message, HUB's not hiding, he's on the road. Probably trying to get away!!! Keep pushing.
GOOD POINT EAGLES13
Yes, just a matter of time, till the next NT 10-Q. But, your are right Litchfield, the financials will tell it all. Hopefully, We will all be happy stockholders!!
Seems to be our only alternative, which is too bad.
Sadly, this is what it has come down to. Eagles13, I've gone to Lexi Luu's facebook site and started asking questions there about Hub and his whereabouts. Will start hitting the other sites, if we don't get some response.
Communication was strong, now, dead. Have you checked the obituaries, maybe Hub is gone!! No news or communication makes you wonder. If he is still breathing, he has turned out to be one PISS POOR CEO. Reneged on his promises about about being truthful and open to the shareholders.
SC 13G just issued on SEC
"He has done nothing substantial." You can say that again!! Has anybody checked the obituaries? Remember, from his earlier updates when he talked about keeping stock holders informed. Once you get to the top, your integrity goes out the window. There is no excuse for this silence.
Still no reason to ignore the stockholders!!
Worth a try, sitting idly by isn't getting us (stockholders) anywhere. Remember, he's the one who talked about transparency. Haven't heard from him since March 3rd. Remember this is our money that's invested. I tweeted two different stock boards. Turn up the heat.
That's the intent. He's the one who talked about transparency. Haven't heard from him since March 3rd. Remember it's our money that is invested. I tweeted two different stock boards.
On the website, you can send them an email by clicking on "contact". Probably won't get any news from them either, but maybe worth a try.
That's the purpose, make him uncomfortable, then he might get the message. Talk to the stockholders.